Cat. No.: HY-B0294

Flubendazole

8 Cited Publications

Customer Review

Based on 8 publication(s) in Google Scholar

Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites.

For research use only. We do not sell to patients.

Purity: 99.05%
CAS No.: 31430-15-6
Formula: C₁₆H₁₂FN₃O₃
Molecular Weight:313.28

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Flubendazole Chemical Structure

CAS No.: 31430-15-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[2]

STAT3

All Parasite Isoforms :

All STAT Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
BT-549	IC₅₀	0.125 μM Compound: 28; 65	Anticancer activity against human BT-549 cells assessed as cell growth inhibition by MTS assay Anticancer activity against human BT-549 cells assessed as cell growth inhibition by MTS assay	[PMID: 33650861]
Hs-578T	IC₅₀	0.125 μM Compound: 28; 65	Anticancer activity against human Hs-578T cells assessed as cell growth inhibition by MTS assay Anticancer activity against human Hs-578T cells assessed as cell growth inhibition by MTS assay	[PMID: 33650861]
MDA-MB-231	IC₅₀	0.25 μM Compound: 28; 65	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTS assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTS assay	[PMID: 33650861]
MDA-MB-231	IC₅₀	0.5 μM Compound: 28; 65	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 33650861]
MDA-MB-231	IC₅₀	0.75 μM Compound: 14	Antiproliferative activity against human MDA-MB-231 cells assessed reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 37595546]
PC-3M	EC₅₀	1.43 μM Compound: Flubendazole	Cytotoxicity against human PC3M cells assessed as reduction in cell viability after 48 hrs by cyquant reagent based fluorescence spectrometric assay Cytotoxicity against human PC3M cells assessed as reduction in cell viability after 48 hrs by cyquant reagent based fluorescence spectrometric assay	[PMID: 29288939]

In Vitro

Flubendazole (0-400 μM; 48 h) inhibits human colorectal cancer (CRC) cells proliferation^[1].
Flubendazole (0.3-1.2 μM; 48 h) induces apoptosis in CRC cells^[1].
Flubendazole (0.3-1.2 μM; 24 h) induces autophagy initiation by inactivating mTOR and P62, and upregulating LC3-I/II in CRC cells^[1].
Flubendazole (0.3-1.2 μM; 24 h) strongly reduces the expression of P-STAT3 in a dose and time-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

CRC cells (HCT116, RKO and SW480)
Concentration:

0-400 μM
Incubation Time:

48 h
Result:

Effectively reduces the viability of CRC cells (HCT116, RKO and SW480) in a concentration-dependent manner, with an IC₅₀ of 2-5 μM.

Apoptosis Analysis^[1]

Cell Line:

CRC cells (HCT116, RKO and SW480)
Concentration:

0.3, 0.6, 1.2 μM
Incubation Time:

48 h
Result:

Increased the proportion of apoptotic cells in a dose-dependent manner.
Dose-dependently effectively increases caspase-3 activity.

Cell Autophagy Assay^[1]

Cell Line:

CRC cells (HCT116, RKO and SW480)
Concentration:

0.3, 0.6, 1.2 μM
Incubation Time:

24 h
Result:

Induced autophagy initiation by inactivating mTOR and P62, and upregulating LC3-I/II, which are classical marker of autophagy.

Western Blot Analysis^[1]

Cell Line:

CRC cells (HCT116, RKO and SW480)
Concentration:

0.3, 0.6, 1.2 μM
Incubation Time:

24 h
Result:

Strongly reduced the expression of phosphorylated STAT3 (P-STAT3) in a dose and time-dependent manner.
No obvious change in total STAT3 expression.
Decreased expression of MCL1 and survivin in a dose-dependent manner.

In Vivo

Flubendazole (10, 30 mg/kg; i.p; every other day; 14 days) inhibits growth of CRC tumor xenografts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female BALB/c athymic nude mice (6-8 weeks) with HCT116 cells^[1]
Dosage:

10 or 30 mg/kg
Administration:

Intraperitoneal injection; every other day; 14 days
Result:

Markedly reduced the tumor volume.
Significantly reduces the protein level of P-STAT3, promotes autophagy and induces apoptosis in vivo.

Chemical Information

CAS No. 31430-15-6
Appearance Solid
Molecular Weight 313.28
Formula C₁₆H₁₂FN₃O₃
Color White to off-white
SMILES

O=C(OC)NC1=NC2=CC=C(C(C3=CC=C(F)C=C3)=O)C=C2N1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All

Sort by:

Journal Impact Factor

Theranostics

Microbial and genetic-based framework identifies drug targets in inflammatory bowel disease. [Abstract]

2021 Jun 1;11(15):7491-7506. PMID: 34158863
Int J Biol Sci

Drug Repurposing Flubendazole to Suppress Tumorigenicity via PCSK9-dependent Inhibition and Potentiate Lenvatinib Therapy for Hepatocellular Carcinoma. [Abstract]

2023 Apr 23;19(7):2270-2288. PMID: 37151886
Acta Pharmacol Sin

Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle. [Abstract]

2022 Jan;43(1):194-208. PMID: 34433903
Biochem Pharmacol

Flubendazole inhibits cervical carcinoma by targeting DHODH to induce ferroptosis and mitophagy. [Abstract]

2025 Aug 28;242(Pt 1):117287. PMID: 40885318
Commun Biol

Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes. [Abstract]

2024 Jan 24;7(1):123. PMID: 38267545
ACS Omega

Computational Approaches to Identify Molecules Binding to Mycobacterium tuberculosis KasA. [Abstract]

2020 Nov 15;5(46):29935-29942. PMID: 33251429
J Cell Mol Med

Repurposing flubendazole for glioblastoma ferroptosis by affecting xCT and TFRC proteins. [Abstract]

2024 Nov;28(22):e70188. PMID: 39543084
Research Square Preprint

2021 Jul.

Solvent & Solubility

In Vitro:

DMSO : 4.17 mg/mL (13.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1920 mL

15.9602 mL

31.9203 mL

5 mM

0.6384 mL

3.1920 mL

6.3841 mL

10 mM

0.3192 mL

1.5960 mL

3.1920 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 5 mg/mL (15.96 mM); Suspended solution; Need ultrasonic

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Shichong Lin, et al. Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy. J Exp Clin Cancer Res. 2019 Jul 8;38(1):293. [Content Brief]

[2]. Zhou X, et al. Flubendazole inhibits glioma proliferation by G2/M cell cycle arrest and pro-apoptosis. Cell Death Discov. 2018 Feb 14;4:18. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1920 mL	15.9602 mL	31.9203 mL	79.8008 mL
	5 mM	0.6384 mL	3.1920 mL	6.3841 mL	15.9602 mL
	10 mM	0.3192 mL	1.5960 mL	3.1920 mL	7.9801 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Flubendazole

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Ferroptosis Compound Library

Anti-COVID-19 Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Protein-protein Interaction Inhibitor Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

FDA Kinase Inhibitor Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Flubendazole

All Parasite Isoforms

All STAT Isoforms

Biological Activity

Chemical Information

Publications (8)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Flubendazole Related Classifications

Cat. No.: HY-B0294